PODD — Insulet Corp.

Summary of Insulet Corporation (PODD) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $802 million, up 23.5% year-over-year (22.7% on a constant currency basis).
• U.S. Omnipod Revenue: Grew 20% driven by demand from both type 1 and type 2 customers.
• International Omnipod Revenue: Increased over 35% on a reported basis (33% constant currency).
• Adjusted Gross Margin: 72.9%, up 320 basis points year-over-year.
• Adjusted Operating Margin: 19.3%, up 140 basis points year-over-year.
• Adjusted EPS: $1.66, a 41.5% increase from $1.17 in the prior year.
• Free Cash Flow: $145 million generated year-to-date.
• Cash Position: $535 million in cash and investments, with a $500 million revolving credit facility available.

2. Strategic Updates and Business Highlights

• Strong demand for Omnipod products, with a rebound in new customer starts, particularly in the U.S. where over 85% of new starts came from MDI users.
• Omnipod 5 became the #1 insulin pump for new users in Australia, and the company launched in Spain, expanding its global reach.
• Over 32,000 healthcare providers in the U.S. are now prescribing Omnipod, a 27% increase year-over-year.
• The company is enhancing its commercial model to better serve type 2 diabetes patients, focusing on onboarding support and retention strategies.
• Introduction of the Omnipod Discover platform, which aids in monitoring and personalizing therapy, with over 12,000 users and 1,600 healthcare professionals engaged.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Updated to 20%-22% for total company revenue and 17%-19% for U.S. Omnipod revenue.
• International Revenue Growth: Raised to 30%-32% due to strong first-half performance.
• Third Quarter Guidance: Anticipates Omnipod revenue growth of 18%-20% and total company revenue growth of 17.5%-19.5%.
• 2027 Preliminary Outlook: Expects growth consistent with or better than mid-teens exit rate from 2026, factoring in new product launches and sales force expansion.

4. Bad News, Challenges, or Points of Concern

• Type 2 Customer Retention: The company identified lower-than-expected retention rates among type 2 customers, particularly in the first 90 days of therapy, leading to a cautious outlook.
• Execution Challenges: Acknowledgment that the company should have adapted its model sooner to meet the needs of type 2 customers.
• Market Dynamics: Concerns about competition and pricing pressures, particularly with new entrants in the market, although the company maintains a stable pricing strategy.
• Reassessment of Long-Term Growth: The need to revisit long-term revenue growth assumptions based on recent learnings from type 2 market dynamics.

5. Notable Q&A Insights

• Retention vs. Utilization: The primary issue affecting type 2 customers is retention rather than utilization, with the first 90 days being critical for onboarding success.
• Prescriber Impact: Retention rates are higher among patients treated by endocrinologists compared to those by primary care providers, highlighting the importance of educating PCPs.
• Confidence in Long-Term Opportunity: Despite current challenges, management remains confident in the long-term potential of the type 2 market and the overall growth of the AID segment.
• Actions to Improve Retention: Initiatives include enhancing customer support during onboarding, changing sales force compensation to focus on retention, and leveraging the Omnipod Discover platform to improve patient engagement.

This summary encapsulates the key points from Insulet's Q2 2026 earnings call, providing a balanced view of the company's performance, strategic direction, and challenges faced.